BY Clayton Boldt

Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An estimated 32,110 new cases will be diagnosed in 2019, with nearly 13,000 deaths caused by the disease. Certain patients have what is known as high-risk multiple myeloma (HRMM), meaning they have distinct molecular features that lead to more rapid progression and poorer outcomes.

The High-Risk Multiple Myeloma...

Robert Orlowski, M.D., Ph.D., leads a Moon Shot dedicated to finding new, longer-lasting options for patients with high-risk multiple myeloma, including a variety of immunotherapy options.

BY Clayton Boldt

Prostate cancer is the most common cancer diagnosed in American men, and the second leading cause of cancer death in men. While hormone-based...

BY Clayton Boldt

For the first time, a new drug from the field of immuno-oncology has proven to extend survival for patients with advanced kidney cancer, a...

BY Clayton Boldt

MD Anderson has appointed former U.S. Public Health Service four-star Admiral Joxel Garcia, M.D. as the inaugural executive director of the cancer prevention and control platform, part of MD Anderson’s Moon Shots Program.

“I’m honored to join the No. 1 cancer center in the nation,” said Garcia. “It’s truly exciting to join the MD Anderson family and work with world-class leaders, researchers and clinicians.”

The Moon Shots...

Former U.S. Public Health Service four-star Admiral Joxel Garcia, M.D.